Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Sample Storage at -20°C and -70°C – V 2.0

Posted on By

BA-BE Studies: SOP for Sample Storage at -20°C and -70°C – V 2.0

Standard Operating Procedure for Sample Storage at -20°C and -70°C in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/075/2025
Supersedes SOP/BA-BE/075/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for the proper storage of biological samples, including plasma, serum, and whole blood, at -20°C and -70°C in Bioavailability/Bioequivalence (BA/BE) studies, ensuring stability and traceability of samples until analysis.

2. Scope

This SOP applies to all study personnel involved in transferring, placing, monitoring, and maintaining biological samples in temperature-controlled storage units at -20°C and -70°C at the clinical site or bioanalytical lab.

3. Responsibilities

  • Lab Technician: Places and retrieves samples from designated freezers, logs entries, and ensures temperature stability.
  • Clinical Research Coordinator (CRC): Verifies freezer allocation and sample integrity.
  • QA Officer: Reviews storage records and conducts periodic audits.
See also  BA-BE Studies: SOP for Administration of Study Drug in Fed State - V 2.0

4. Accountability

The Bioanalytical Department Head is accountable for ensuring that all biological samples are stored under validated conditions and documentation is maintained for audit and regulatory purposes.

5. Procedure

5.1 Freezer Qualification and Monitoring

  1. Ensure that freezers are:
    • Qualified and calibrated as per equipment validation protocol
    • Maintained between -18°C to -22°C (for -20°C freezer)
    • Maintained between -68°C to -75°C (for -70°C freezer)
  2. Install 24×7 temperature monitoring system with alarm notifications.
  3. Document daily temperatures in Annexure-1: Freezer Temperature Monitoring Log.

5.2 Sample Placement

  1. Verify that samples are:
    • Correctly labelled with subject ID, timepoint, and aliquot number
    • Pre-frozen at controlled conditions before transfer (if applicable)
  2. Log freezer ID, rack number, and sample code in Annexure-2: Sample Storage Log.

5.3 Storage Layout and Access

  1. Assign fixed racks and box positions for each study to avoid misplacement.
  2. Restrict access to trained lab staff and record entries in Annexure-3: Freezer Access Log.
See also  BA-BE Studies: SOP for Developing Informed Consent Documents - V 2.0

5.4 Sample Retrieval and Transfer

  1. During sample transfer to bioanalytical labs:
    • Log retrieval time and temperature condition
    • Ensure transport containers are pre-cooled
  2. Update Annexure-2 and generate chain-of-custody documentation.

5.5 Backup Plan for Power Failure

  1. Ensure each freezer is connected to a UPS or backup generator.
  2. Keep dry ice and portable -70°C freezer ready for emergency transfer.

5.6 Deviation and Alarm Management

  1. Record any out-of-limit temperature excursions in Annexure-4: Temperature Deviation Log.
  2. Notify QA and PI for impact assessment and resolution.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • ID: Identification

7. Documents

  1. Freezer Temperature Monitoring Log – Annexure-1
  2. Sample Storage Log – Annexure-2
  3. Freezer Access Log – Annexure-3
  4. Temperature Deviation Log – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA Guidance on BA/BE Studies
  • WHO Laboratory Biosafety Manual
See also  BA-BE Studies: SOP for Ethics Committee Submission Requirements - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Freezer Temperature Monitoring Log

Date Freezer ID Temperature (°C) Time Checked By Remarks
17/04/2025 FZ-075 -70.2 08:00 Ravi Nair Normal

Annexure-2: Sample Storage Log

Subject ID Sample Code Freezer ID Rack No. Stored By Storage Time
VOL-075 VOL075/P1/2h/A1 FZ-02 R2 Sunita Reddy 09:10

Annexure-3: Freezer Access Log

Date Time Accessed By Purpose Freezer ID
17/04/2025 11:00 Nisha Verma Sample retrieval FZ-075

Annexure-4: Temperature Deviation Log

Date Time Observed Temp Duration Cause Action Taken Reviewed By
16/04/2025 03:30 -64.5°C 25 min Power issue Transferred to backup freezer Dr. Arvind Shah

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial release Process definition QA Head
17/04/2025 2.0 Expanded deviation management and access logs Audit requirement QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Documentation and Yield Calculation for Solvent Recovery – V 2.0
Next Post: Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version